HK1067966A1 - Quinoline derivatives in combination with 5-fu or cpt-11 for use in the treatment of cancer - Google Patents
Quinoline derivatives in combination with 5-fu or cpt-11 for use in the treatment of cancerInfo
- Publication number
- HK1067966A1 HK1067966A1 HK05101490.8A HK05101490A HK1067966A1 HK 1067966 A1 HK1067966 A1 HK 1067966A1 HK 05101490 A HK05101490 A HK 05101490A HK 1067966 A1 HK1067966 A1 HK 1067966A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cpt
- cancer
- treatment
- combination
- quinoline derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/116,117 US20030028018A1 (en) | 2000-09-11 | 2002-04-05 | Quinolinone derivatives |
PCT/US2003/010463 WO2003087095A1 (en) | 2002-04-05 | 2003-04-04 | Quinolinone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1067966A1 true HK1067966A1 (en) | 2005-04-22 |
Family
ID=29248193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05101490.8A HK1067966A1 (en) | 2002-04-05 | 2005-02-22 | Quinoline derivatives in combination with 5-fu or cpt-11 for use in the treatment of cancer |
Country Status (25)
Country | Link |
---|---|
US (3) | US20030028018A1 (pt) |
EP (1) | EP1497287B1 (pt) |
JP (1) | JP2005527587A (pt) |
KR (1) | KR101035894B1 (pt) |
CN (1) | CN1659165A (pt) |
AP (1) | AP2070A (pt) |
AT (1) | ATE489092T1 (pt) |
AU (1) | AU2003226275B2 (pt) |
BR (1) | BR0308996A (pt) |
CA (1) | CA2481055C (pt) |
DE (1) | DE60335096D1 (pt) |
EA (1) | EA010393B1 (pt) |
EC (1) | ECSP045411A (pt) |
ES (1) | ES2357289T3 (pt) |
HK (1) | HK1067966A1 (pt) |
HR (1) | HRP20041031B1 (pt) |
IL (2) | IL164324A0 (pt) |
MA (1) | MA28122A1 (pt) |
MX (1) | MXPA04009739A (pt) |
NO (1) | NO331021B1 (pt) |
NZ (1) | NZ536068A (pt) |
PL (1) | PL209412B1 (pt) |
PT (1) | PT1497287E (pt) |
SG (1) | SG143985A1 (pt) |
WO (1) | WO2003087095A1 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001293233A1 (en) | 2000-09-01 | 2002-03-13 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
EP1650203B1 (en) * | 2000-09-11 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
US7642278B2 (en) * | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
WO2003004488A1 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
US7169788B2 (en) | 2001-10-30 | 2007-01-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
EP1545529A4 (en) * | 2002-09-30 | 2010-03-03 | Bristol Myers Squibb Co | NEW TYROSINE KINASE HEMMER |
BR0316229A (pt) * | 2002-11-13 | 2005-10-04 | Chiron Corp | Métodos de tratamento de câncer e métodos relacionados |
JP4836788B2 (ja) * | 2003-07-23 | 2011-12-14 | エグゼリクシス, インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
JP4890255B2 (ja) * | 2003-11-07 | 2012-03-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩 |
WO2005048948A2 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Urea derivatives as kinase modulators |
JP5019884B2 (ja) * | 2004-02-20 | 2012-09-05 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 炎症プロセスおよび転移プロセスの調節 |
RU2007101509A (ru) * | 2004-06-17 | 2008-07-27 | Уайт (Us) | Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин |
MXPA06014798A (es) * | 2004-06-17 | 2007-06-22 | Wyeth Corp | Antagonistas del receptor de hormona para liberar gonadotropina. |
CA2587853A1 (en) * | 2004-11-23 | 2006-06-01 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
PL2301546T3 (pl) | 2005-01-27 | 2015-03-31 | Novartis Ag | Leczenie guzów z przerzutami |
US7534796B2 (en) * | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
US7538113B2 (en) * | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US7582634B2 (en) * | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
DK1885187T3 (da) | 2005-05-13 | 2013-12-09 | Novartis Ag | Fremgangsmåde til behandling af lægemiddelresistent cancer |
JP5545925B2 (ja) | 2005-05-17 | 2014-07-09 | ノバルティス アーゲー | ヘテロ環化合物の合成方法 |
US7531542B2 (en) * | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
WO2006127926A2 (en) * | 2005-05-23 | 2006-11-30 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
US7582636B2 (en) * | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
MY148529A (en) | 2005-11-29 | 2013-04-30 | Novartis Ag | Formulations of quinolinones |
JP2009523410A (ja) | 2005-12-08 | 2009-06-25 | ノバルティス アクチエンゲゼルシャフト | 遺伝子転写に対するfgfr3の阻害剤の効果 |
CN100488960C (zh) * | 2006-03-09 | 2009-05-20 | 中国药科大学 | 2-位取代的喹诺酮类化合物及其在制药中的应用 |
US8138205B2 (en) * | 2006-07-07 | 2012-03-20 | Kalypsys, Inc. | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
JP5280357B2 (ja) * | 2006-07-07 | 2013-09-04 | スティーブン・ピー・ガベック | Pde4の二環式ヘテロアリール阻害剤 |
AU2011237642B2 (en) | 2010-04-06 | 2014-05-01 | Brigham Young University | Antimetastatic compounds |
WO2012027392A2 (en) * | 2010-08-24 | 2012-03-01 | Brigham Young University | Antimetastatic compounds |
WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
EP2809312A1 (en) | 2012-01-31 | 2014-12-10 | Novartis AG | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
IN2014DN10801A (pt) | 2012-07-11 | 2015-09-04 | Novartis Ag | |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
SI3057964T1 (sl) | 2013-10-14 | 2020-03-31 | Eisai R&D Management Co., Ltd. | Selektivno substituirane spojine kinolina |
JP6483666B2 (ja) | 2013-10-14 | 2019-03-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
EP2977374A1 (en) | 2014-07-21 | 2016-01-27 | Université de Strasbourg | Molecules presenting dual emission properties |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
CN108003150A (zh) * | 2016-10-31 | 2018-05-08 | 河南工业大学 | 4-杂芳基喹啉酮衍生物的制备方法及其应用 |
MX2020000135A (es) | 2017-06-27 | 2020-07-22 | Janssen Pharmaceutica Nv | Nuevos compuestos de quinolinona. |
EP3717483B1 (en) | 2017-11-24 | 2023-09-06 | Janssen Pharmaceutica NV | Pyrazolopyridinone compounds |
BR112020010012A2 (pt) | 2017-11-24 | 2020-10-13 | Janssen Pharmaceutica Nv | compostos de pirazolopiridinona |
CN108516973A (zh) * | 2018-03-30 | 2018-09-11 | 广西师范大学 | 3-苯并噻唑-1-(3-二甲氨基)丙基喹啉-4-酮衍生物及其制备方法和应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8A (en) * | 1836-08-10 | T Blanchard | Machine for cutting scores around ships' tackle blocks and dead eyes | |
US102369A (en) * | 1870-04-26 | Improvement in pumps | ||
US158224A (en) * | 1874-12-29 | Improvement in eye-cups | ||
US162252A (en) * | 1875-04-20 | Improvement in safety-catches for elevators | ||
US152904A (en) * | 1874-07-14 | Improvement in rotary pumps | ||
US37650A (en) * | 1863-02-10 | Improvement in apparatus for obtaining profiles of submarine beds | ||
US508800A (en) * | 1893-11-14 | Trustees | ||
US128993A (en) * | 1872-07-16 | Improvement in furnaces for reducing iron ores | ||
US36256A (en) * | 1862-08-19 | Improvement in sewing-m ach ines | ||
US27379A (en) * | 1860-03-06 | Improvement in seeding-machines | ||
US155114A (en) * | 1874-09-15 | Improvement in methods of laying and forming cast-iron pipes | ||
US6A (en) * | 1836-08-10 | Thomas blanghard | ||
US162251A (en) * | 1875-04-20 | Improvement in interfering-pads for horses | ||
US207883A (en) * | 1878-09-10 | Improvement in drafting-pencils | ||
US290153A (en) * | 1883-12-11 | Beer-scale | ||
US63A (en) * | 1836-10-20 | Kravxiig | ||
US232861A (en) * | 1880-10-05 | Machine for dressing millstones | ||
US7A (en) * | 1836-08-10 | Thomas blanchard | ||
US509717A (en) * | 1893-11-28 | beach | ||
US129025A (en) * | 1872-07-16 | Improvement in strainer-pipes | ||
US747771A (en) * | 1903-04-16 | 1903-12-22 | Rudolf Richter | Machine for harvesting potatoes or similar root crops. |
US797376A (en) * | 1905-05-19 | 1905-08-15 | John P Schneider Sr | Vise. |
US1086705A (en) * | 1913-06-04 | 1914-02-10 | Frank O Havener | Cigar-moistener. |
US2363459A (en) * | 1944-02-19 | 1944-11-21 | Draper Corp | Picker stick checking mechanism |
US3663606A (en) * | 1966-06-21 | 1972-05-16 | Mitsui Toatsu Chemicals | Organic imino-compounds |
US4659657A (en) * | 1982-12-24 | 1987-04-21 | Bayer Aktiengesellschaft | Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases |
DE3634066A1 (de) * | 1986-10-07 | 1988-04-21 | Boehringer Mannheim Gmbh | Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
DE3932953A1 (de) * | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5151360A (en) * | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
USRE37650E1 (en) * | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5856115A (en) * | 1991-05-24 | 1999-01-05 | Fred Hutchinson Cancer Research Center | Assay for identification therapeutic agents |
ES2193143T3 (es) * | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
JP3441246B2 (ja) * | 1995-06-07 | 2003-08-25 | 富士写真フイルム株式会社 | 光重合性組成物 |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5942385A (en) * | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
WO1997048697A1 (en) * | 1996-06-19 | 1997-12-24 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
US6111110A (en) * | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
DE19756235A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
US6174912B1 (en) * | 1998-08-21 | 2001-01-16 | Dupont Pharmaceuticals Company | Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists |
US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
WO2000071129A1 (en) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
KR100298572B1 (ko) * | 1999-08-19 | 2001-09-22 | 박찬구 | 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법 |
DE60018782T2 (de) | 1999-10-19 | 2006-04-06 | Merck & Co., Inc. | Tyrosin kinase inhibitoren |
EE05107B1 (et) * | 1999-10-19 | 2008-12-15 | Merck & Co., Inc. | Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine |
US6313138B1 (en) * | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6420382B2 (en) * | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2001293233A1 (en) * | 2000-09-01 | 2002-03-13 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
EP1650203B1 (en) * | 2000-09-11 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
WO2003004488A1 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
US20030159702A1 (en) * | 2002-01-21 | 2003-08-28 | Lindell Katarina E.A. | Formulation and use manufacture thereof |
AU2003288899B2 (en) * | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
BR0316229A (pt) * | 2002-11-13 | 2005-10-04 | Chiron Corp | Métodos de tratamento de câncer e métodos relacionados |
US6774327B1 (en) * | 2003-09-24 | 2004-08-10 | Agilent Technologies, Inc. | Hermetic seals for electronic components |
JP4890255B2 (ja) * | 2003-11-07 | 2012-03-07 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩 |
WO2006122950A1 (en) * | 2005-05-18 | 2006-11-23 | M & G Polimeri Italia S.P.A. | Polyester composition |
-
2002
- 2002-04-05 US US10/116,117 patent/US20030028018A1/en not_active Abandoned
-
2003
- 2003-04-04 AT AT03746614T patent/ATE489092T1/de active
- 2003-04-04 PL PL372871A patent/PL209412B1/pl unknown
- 2003-04-04 NZ NZ536068A patent/NZ536068A/en not_active IP Right Cessation
- 2003-04-04 KR KR1020047015851A patent/KR101035894B1/ko not_active IP Right Cessation
- 2003-04-04 CA CA2481055A patent/CA2481055C/en not_active Expired - Lifetime
- 2003-04-04 AU AU2003226275A patent/AU2003226275B2/en not_active Expired
- 2003-04-04 DE DE60335096T patent/DE60335096D1/de not_active Expired - Lifetime
- 2003-04-04 EP EP03746614A patent/EP1497287B1/en not_active Expired - Lifetime
- 2003-04-04 JP JP2003584051A patent/JP2005527587A/ja active Pending
- 2003-04-04 WO PCT/US2003/010463 patent/WO2003087095A1/en active Application Filing
- 2003-04-04 PT PT03746614T patent/PT1497287E/pt unknown
- 2003-04-04 MX MXPA04009739A patent/MXPA04009739A/es active IP Right Grant
- 2003-04-04 CN CN038129094A patent/CN1659165A/zh active Pending
- 2003-04-04 AP APAP/P/2004/003166A patent/AP2070A/en active
- 2003-04-04 BR BR0308996-7A patent/BR0308996A/pt not_active Application Discontinuation
- 2003-04-04 IL IL16432403A patent/IL164324A0/xx unknown
- 2003-04-04 ES ES03746614T patent/ES2357289T3/es not_active Expired - Lifetime
- 2003-04-04 SG SG200606999-1A patent/SG143985A1/en unknown
- 2003-04-04 EA EA200401318A patent/EA010393B1/ru not_active IP Right Cessation
-
2004
- 2004-09-28 IL IL164324A patent/IL164324A/en not_active IP Right Cessation
- 2004-10-04 MA MA27887A patent/MA28122A1/fr unknown
- 2004-11-03 HR HRP20041031AA patent/HRP20041031B1/hr not_active IP Right Cessation
- 2004-11-03 NO NO20044776A patent/NO331021B1/no not_active IP Right Cessation
- 2004-11-05 EC EC2004005411A patent/ECSP045411A/es unknown
-
2005
- 2005-02-22 HK HK05101490.8A patent/HK1067966A1/xx not_active IP Right Cessation
-
2007
- 2007-10-02 US US11/866,296 patent/US20080070906A1/en not_active Abandoned
-
2010
- 2010-01-04 US US12/651,612 patent/US20100184754A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1067966A1 (en) | Quinoline derivatives in combination with 5-fu or cpt-11 for use in the treatment of cancer | |
HK1089155A1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
PL370029A1 (en) | 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer | |
IL178012A0 (en) | Diphenyl-indol-2-on compounds and their use in the treatment of cancer | |
AU2003284808A8 (en) | The derivatives of pyridone and the use of them | |
AU2003237367A1 (en) | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer | |
IL163691A0 (en) | 5-Pphenylthiazole derivatives and use as pi3 kinase | |
HK1097256A1 (en) | Pyrizdazine derivatives and their use as therapeutic agents | |
HK1091199A1 (en) | Quinazoline derivatives and use thereof in the manufacture of medicaments | |
HK1086488A1 (en) | Compound and use thereof for the treatment of cancer | |
IL180138A0 (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer | |
IL173398A0 (en) | Pyridyl derivatives and their use as therapeutic agents | |
HK1079518A1 (en) | Quinazolinone derivatives and their use as cb agonists | |
ZA200410409B (en) | Use of thio-oxindole derivatives in treatment of hormonerelated conditions | |
HK1075844A1 (en) | Formulation and methods for the treatment of thrombocythemia | |
IL173416A0 (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
IL178261A0 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
AU2002346644A1 (en) | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer | |
AU2002352498A1 (en) | Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers | |
EP1575582A4 (en) | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME | |
IL182385A0 (en) | Pyridine derivatives and the preparation and the therapeutic use thereof | |
HK1105288A1 (en) | Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer | |
ZA200606065B (en) | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies | |
AU2003250831A1 (en) | Use of hec1 antagonists in the treatment of proliferative disorders and cancer | |
IL162941A0 (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190331 |